Compare FENG & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FENG | QNCX |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 17.1M |
| IPO Year | 2011 | 2019 |
| Metric | FENG | QNCX |
|---|---|---|
| Price | $1.49 | $18.99 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.3K | ★ 168.7K |
| Earning Date | 05-12-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.44 | $0.08 |
| 52 Week High | $3.65 | $20.72 |
| Indicator | FENG | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 40.33 | 84.29 |
| Support Level | N/A | $0.89 |
| Resistance Level | $1.80 | $19.26 |
| Average True Range (ATR) | 0.04 | 1.60 |
| MACD | -0.00 | 0.19 |
| Stochastic Oscillator | 9.37 | 69.13 |
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives all of its revenue from PRC.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.